Radius Health (RDUS) Rating Reiterated by Cantor Fitzgerald

Radius Health (NASDAQ:RDUS)‘s stock had its “buy” rating restated by Cantor Fitzgerald in a research report issued to clients and investors on Thursday. They presently have a $58.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 52.55% from the stock’s current price.

Several other research analysts have also recently weighed in on RDUS. Maxim Group reiterated a “positive” rating on shares of Radius Health in a research note on Friday, September 29th. They noted that the move was a valuation call. Zacks Investment Research cut shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Goldman Sachs Group reiterated a “neutral” rating and set a $45.00 price target on shares of Radius Health in a research note on Friday, October 6th. Jefferies Group dropped their price target on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating on the stock in a research note on Friday, November 3rd. Finally, ValuEngine upgraded shares of Radius Health from a “strong sell” rating to a “sell” rating in a research note on Friday, December 1st. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company. Radius Health currently has an average rating of “Hold” and an average target price of $48.00.

Shares of Radius Health (RDUS) traded up $1.90 during trading on Thursday, hitting $38.02. 1,600,000 shares of the stock traded hands, compared to its average volume of 974,121. The stock has a market cap of $1,780.00, a PE ratio of -7.00 and a beta of 1.10. Radius Health has a 1-year low of $24.66 and a 1-year high of $49.16. The company has a quick ratio of 12.79, a current ratio of 12.87 and a debt-to-equity ratio of 0.53.

Radius Health (NASDAQ:RDUS) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million for the quarter, compared to analyst estimates of $6.90 million. During the same quarter in the previous year, the company earned ($1.07) EPS. equities research analysts expect that Radius Health will post -5.57 EPS for the current fiscal year.

In other news, major shareholder Growth N. V. Biotech acquired 50,000 shares of the firm’s stock in a transaction dated Wednesday, October 25th. The shares were purchased at an average cost of $32.85 per share, for a total transaction of $1,642,500.00. Following the transaction, the insider now directly owns 5,548,799 shares of the company’s stock, valued at $182,278,047.15. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Brent Hatzis-Schoch acquired 1,778 shares of the firm’s stock in a transaction dated Friday, November 10th. The shares were purchased at an average price of $28.09 per share, for a total transaction of $49,944.02. Following the completion of the transaction, the vice president now directly owns 2,278 shares in the company, valued at $63,989.02. The disclosure for this purchase can be found here. Insiders have bought a total of 158,578 shares of company stock worth $4,659,916 over the last 90 days. Insiders own 15.00% of the company’s stock.

Several hedge funds have recently made changes to their positions in RDUS. Legal & General Group Plc raised its position in shares of Radius Health by 14.5% during the 2nd quarter. Legal & General Group Plc now owns 13,372 shares of the biopharmaceutical company’s stock valued at $605,000 after purchasing an additional 1,697 shares during the period. Principal Financial Group Inc. raised its position in shares of Radius Health by 14.1% during the 2nd quarter. Principal Financial Group Inc. now owns 6,809 shares of the biopharmaceutical company’s stock valued at $308,000 after purchasing an additional 839 shares during the period. Swiss National Bank raised its position in shares of Radius Health by 8.7% during the 2nd quarter. Swiss National Bank now owns 54,000 shares of the biopharmaceutical company’s stock valued at $2,442,000 after purchasing an additional 4,300 shares during the period. Teachers Advisors LLC raised its position in shares of Radius Health by 24.2% during the 2nd quarter. Teachers Advisors LLC now owns 67,101 shares of the biopharmaceutical company’s stock valued at $3,035,000 after purchasing an additional 13,077 shares during the period. Finally, TIAA CREF Investment Management LLC raised its position in shares of Radius Health by 17.3% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 100,526 shares of the biopharmaceutical company’s stock valued at $4,547,000 after purchasing an additional 14,796 shares during the period.

TRADEMARK VIOLATION WARNING: “Radius Health (RDUS) Rating Reiterated by Cantor Fitzgerald” was originally posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.truebluetribune.com/2018/01/20/radius-health-rdus-rating-reiterated-by-cantor-fitzgerald.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply